Klaus Dugi is CEO of Vandria and Chief Medical Advisor at the VC Fund Limani Partners. Klaus is also a Board member at AOBiome Therapeutics, Ferring Ventures, Notify Therapeutics, and Cytoki. Klaus spent 18 years in the pharmaceutical industry with Boehringer Ingelheim and Ferring Pharmaceuticals, including 8 years as CMO. Klaus oversaw the development, approval and launch of several medicines including four which have achieved blockbuster status. Klaus was a PostDoc at the NIH in Bethesda, US, conducting research in metabolic diseases. He received his clinical training in internal medicine and endocrinology at Heidelberg University where he continues to teach.